Compare CULP & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CULP | PRPO |
|---|---|---|
| Founded | 1972 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 44.4M |
| IPO Year | 1994 | 2000 |
| Metric | CULP | PRPO |
|---|---|---|
| Price | $2.94 | $28.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 30.5K | 8.7K |
| Earning Date | 03-11-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $213,237,000.00 | $18,532,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 21.95 |
| 52 Week Low | $2.73 | $4.90 |
| 52 Week High | $5.57 | $29.53 |
| Indicator | CULP | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 37.96 | 55.93 |
| Support Level | $2.73 | $22.58 |
| Resistance Level | $3.60 | $28.76 |
| Average True Range (ATR) | 0.19 | 1.45 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 30.90 | 61.11 |
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.